Advertisement
Screener

Processa Pharmaceuticals, Inc. (PCSA) Sales Revenue, Services, Net (Deprecated 2018-01-31)

2.8 / 5 stars · 68/120 Roast Me

Processa Pharmaceuticals, Inc. Sales Revenue, Services, Net (Deprecated 2018-01-31)

Processa Pharmaceuticals, Inc. (PCSA) reported Sales Revenue, Services, Net (Deprecated 2018-01-31) of $28.87 thousand for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-12-01.

Discontinued › Expense Statement › Operating Expenses

us-gaap:SalesRevenueServicesNet · last filed 2015-12-01

  • Processa Pharmaceuticals, Inc. sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
  • Processa Pharmaceuticals, Inc. sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2015-06-30 was $20.04K, a 35.30% decline year-over-year.
  • Processa Pharmaceuticals, Inc. sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2015-03-31 was $8.83K, a 31.55% decline year-over-year.
  • Processa Pharmaceuticals, Inc. sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2014-12-31 was $13.09K.
  • Processa Pharmaceuticals, Inc. sales revenue, services, net (deprecated 2018-01-31) for fiscal 2014 was $92.96K, a 271.85% increase from fiscal 2013.
  • Processa Pharmaceuticals, Inc. sales revenue, services, net (deprecated 2018-01-31) for fiscal 2013 was $25.00K.
Period endSales Revenue, Services, Net (Deprecated 2018-01-31) 3 monthSales Revenue, Services, Net (Deprecated 2018-01-31) 6 monthSales Revenue, Services, Net (Deprecated 2018-01-31) 9 monthSales Revenue, Services, Net (Deprecated 2018-01-31) 12 monthSales Revenue, Services, Net (Deprecated 2018-01-31) 36 month
2015-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-12-01
$20.04K
derived: sum of 2 quarters · filed 2015-12-01
$28.87K
10-Q · filed 2015-12-01
$41.96K
derived: sum of 4 quarters · filed 2015-12-01
2015-06-30$20.04K
10-Q · filed 2015-08-19
$28.87K
10-Q · filed 2015-08-19
$41.96K
derived: sum of 3 quarters · filed 2015-08-19
$77.96K
derived: sum of 4 quarters · filed 2015-12-01
2015-03-31$8.83K
10-Q · filed 2015-05-15
$21.92K
derived: sum of 2 quarters · filed 2015-05-15
$57.92K
derived: sum of 3 quarters · filed 2015-12-01
$88.89K
derived: sum of 4 quarters · filed 2015-12-01
2014-12-31$13.09K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14
$49.09K
derived: sum of 2 quarters · filed 2015-12-01
$80.06K
derived: sum of 3 quarters · filed 2015-12-01
$92.96K
10-K · filed 2015-04-14
2014-09-30$36.00K
10-Q · filed 2015-12-01
$66.97K
derived: sum of 2 quarters · filed 2015-12-01
$79.87K
10-Q · filed 2015-12-01
2014-06-30$30.98K
10-Q · filed 2015-08-19
$43.88K
10-Q · filed 2015-08-19
2014-03-31$12.90K
10-Q · filed 2015-05-15
$37.90K
10-Q · filed 2014-05-14
2013-12-31$25.00K
10-K · filed 2015-04-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Pulmatrix, Inc. (PULM)United States$0.006B
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59